A ‘milestone’ for psychedelics as clinical trial begins in US with FDA’s blessing

As the first federally approved psychedelics clinical trial begins in the US, there is broad but not total agreement among official bodies over legalising research into hallucinogenic substances.

The first Phase 1 study into psilocin and psilocybin to be approved by the US Food and Drug Administration (FDA) will examine the physiological and psychological effects of the mushroom-derived compounds when delivered orally and sublingually to healthy adults.

...

Need help?

Contact a sales representative right now and don’t wait

Erik Galavis
+34 654 320 547
Email Erik

Pablo Sharrock
+34 722 642 678
Email Pablo

Restricted content. Do you want to read more?

Request report

Interested in buying?
Request more information

MORE INFO

Visit store

Check out our reports
available for purchase

VIEW REPORTS

Request a free sample of this report:

“ A ‘milestone’ for psychedelics as clinical trial begins in US with FDA’s blessing ”

    This file is not available, please fill the form to request your sample page:






    Buy report request information:

    “ A ‘milestone’ for psychedelics as clinical trial begins in US with FDA’s blessing ”






      As the first federally approved psychedelics clinical trial begins in the US, there is broad but not total agreement among official bodies over legalising research into hallucinogenic substances.

      The first Phase 1 study into psilocin and psilocybin to be approved by the US Food and Drug Administration (FDA) will examine the physiological and psychological effects of the mushroom-derived compounds when delivered orally and sublingually to healthy adults.

      ...

      Benefits of subscription plans:

      • Stay informed of any legal and market change in the sector that impacts your organization
      • Maximise resources by getting market and legal data analysis daily in one place
      • Make smart decisions by understanding how the regulatory and market landscape evolves
      • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

      Need help?

      Contact a sales representative right now and don’t wait

      Erik Galavis
      +34 654 320 547
      Email Erik

      Pablo Sharrock
      +34 722 642 678
      Email Pablo